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The impact of calcimimetic agents on the use of different classes
of phosphate binders: Results of recent clinical trials. Cal-
cimimetic agents bind to and activate the calcium-sensing re-
ceptor in the parathyroid glands, lowering the threshold for its
activation by extracellular calcium and diminishing parathyroid
hormone release from parathyroid cells. In three large ran-
domized, controlled trials, cinacalcet given at doses of 30 to
180 mg orally each day was associated with effective reduction
in parathyroid hormone levels over 26 weeks compared with
placebo, and was consistently associated with a decrement in
serum calcium, phosphorus levels, as well as a decrement in
calcium-phosphorus product. In one study, there was a 5% inci-
dence of hypocalcemia (serum calcium levels <7.5 mg/dL on at
least two consecutive measurements) among patients receiving
cinacalcet, and less than 1% of patients receiving standard ther-
apy (P < 0.0001). While there were no demonstrated differences
between groups with regard to use of phosphate binders and vi-
tamin D sterols in these randomized controlled trials, arguably,
the combination of the effects on serum calcium, phosphorus,
and calcium-phosphorus product may bring increased focus on
the increased mortality risk associated with hypocalcemia.
Calcimimetic agents bind to and activate the calcium-
sensing receptor in the parathyroid glands, lowering the
threshold for its activation by extracellular calcium, and
diminishing parathyroid hormone (PTH) release from
parathyroid cells [1]. While a number of calcimimetics
are in various stages of clinical development, Sensipar
(cinacalcet; Amgen, Thousand Oaks, CA, USA) (for-
merly AMG 073) has amassed the greatest amount of ef-
ficacy data and is the only medication currently approved
by the FDA for use in the United States. In three large
randomized, controlled trials, cinacalcet given at doses of
30 to 180 mg orally each day was associated with effective
reduction in PTH levels over 26 weeks compared with
placebo, and was consistently associated with a decre-
ment in calcium and phosphorus levels, as well as a decre-
ment in calcium-phosphorus product [2–5]. In addition
to the demonstrated effect of cinacalcet toward lowering
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PTH levels, the mechanism by which calcium, phospho-
rus, and calcium-phosphorus product decline may be re-
lated to an overall down-regulation of mRNA expression
levels encoding proteins involved in active transcellular
calcium reabsorption in the intestine [6].
Trials comparing cinacalcet to standard therapy
Four trials comparing cinacalcet plus standard treat-
ment [a vitamin D sterol and phosphorus-binding
agent(s)] to placebo plus standard therapy have been
published to date [2–5]. Given that these trials have sim-
ilar design, the specific design of Block et al [2] will be
presented in detail here. Patients receiving hemodialysis
for at least three months with secondary hyperparathy-
roidism (defined as an average of three values of intact
PTH of greater than 300 pg/mL over a 30-day screen-
ing period) despite standard treatment were randomly
assigned to receive either cinacalcet or placebo with con-
current use of standard therapy (i.e., phosphate binders
and vitamin D sterols) in both arms for 26 weeks. Once-
daily doses of cinacalcet were increased from 30 mg to
180 mg guided by PTH. The dose of study drug was not
increased in the presence of hypocalcemia. The goal for
individual patients was to achieve intact PTH levels of
less than 250 pg/mL, and the primary end point for the
trial was the percentage of patients with intact parathy-
roid values within this range during a 14-week efficacy-
assessment phase (the latter 14 weeks of the study). While
dialysate calcium levels remained unchanged throughout
the study, no restrictions were imposed on the dose, type
of, or manipulation of phosphate binders or vitamin D
sterols.
Each of these trials demonstrated similar efficacy for
cinacalcet in the reduction of intact PTH levels. In a re-
port of two trials randomizing a total of 741 patients,
43% of patients receiving cinacalcet plus standard ther-
apy compared with 5% of patients receiving placebo and
standard therapy had their intact PTH values fall below
250 pg/mL over 26 weeks (P < 0.0001) [2]. Similarly sig-
nificant results for cinacalcet compared with placebo in
reducing intact PTH levels to below 250 pg/mL were seen
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Table 1. Effect of cinacalcet plus standard therapy and placebo plus standard therapy on serum measurements of calcium, phosphorus, and the
calcium × phosphorus product
Block et al [2] Quarles et al [3] Lindberg et al [4]
Cinacalcet Placebo Cinacalcet Placebo Cinacalcet Placebo
Calcium
Baseline 9.9 ± 0.0 9.9 ± 0.0 9.6 ± 0.1 9.7 ± 0.1 9.7 ± 0.67 9.7 ± 0.64
Follow-up 9.2 ± 0.0 9.9 ± 0.0 9.2 ± 0.1 9.9 ± 0.1 na na
Percent change −6.8 ± 0.4a 0.4 ± 0.3 −4.6 ± 1.4b 2.6 ± 1.3 −4.7b No change
Phosphorus
Baseline 6.2 ± 0.1 6.2 ± 0.1 6.0 ± 0.2 5.5 ± 0.2 5.6 ± 1.38 6.3 ± 1.42
Follow-up 5.6 ± 0.1 6.0 ± 0.1 5.8 ± 0.2 5.7 ± 0.2 na na
Percent change −8.4 ± 1.3a 0.2 ± 1.3 −2.6 ± 3.4c 7.0 ± 5.5 −7.54e 10.9
Calcium × phosphorus product
Baseline 62 ± 0.8 61 ± 0.8 57.6 ± 1.6 53.4 ± 2.3 53.8 ± 13.63 60.7 ± 13.21
Follow-up 51 ± 0.8 60 ± 0.8 53.1 ± 1.8 56.6 ± 2.3 na na
Percent change −14.6 ± 1.3a 0.5 ± 1.3 −7.9 ± 2.9d 11.0 ± 6.5 −11.9b 10.9
na, not available.
aP < 0.001 for the comparison with the baseline value.
bP < 0.001 comparing treatment groups.
cP = 0.217 comparing treatment groups.
dP = 0.013 comparing treatment groups.
eP = 0.003 comparing treatment groups.
in the trial by Quarles et al (44 vs. 20%, P = 0.029) [3].
In these studies, as well as the study by Lindberg et al
[4], a significantly greater proportion of patients in the
group receiving cinacalcet experienced a ≥30% decrease
in mean PTH from baseline compared with the group
receiving placebo (8%) (P = 0.0001).
Effect of cinacalcet on calcium and phosphorus levels
A decrement in serum calcium, phosphorus, and
calcium × phosphorus product was seen in all trials
(Table 1). Among the trials by Block et al [2], Quarles
et al [3], and Lindberg et al [4], a differential decrement in
serum calcium among patients receiving cinacalcet com-
pared with placebo from baseline to end of study was
demonstrated in all trials of −6.8 vs. +0.4% (P < 0.001),
−4.6 vs. +2.6 (P < 0.001), and −4.7% vs. no change (P <
0.001), respectively. A similar differential decrement in
serum phosphorus among patients receiving cinacalcet
compared with patients receiving placebo was seen in two
of the trials of −8.4 vs. +0.2% (P < 0.001) [2] and −7.5
vs. +10.9% (P = 0.003) [4]. Lastly, a decrement in the
calcium × phosphorus product was also seen universally
for patients receiving cinacalcet compared with those pa-
tients receiving placebo (−14.6 vs. +0.5%, P < 0.001) [2],
(−7.9 vs. +11.0, P = 0.013) [3], and (−11.9 vs. +10.9%,
P < 0.0001) [4].
Further, Block et al reported an incidence of hypocal-
cemia (defined as serum calcium levels <7.5 mg/dL
on at least two consecutive measurements) in 5% of
patients receiving cinacalcet and less than 1% of pa-
tients receiving standard therapy (P < 0.0001). These
episodes were managed by modifying doses of calcium-
containing phosphate-binding agents, vitamin D sterols,
or both. Transient hypocalcemia defined as serum calcium
<7.5 mg/dL was seen in a similar frequency of subjects re-
ceiving cinacalcet (3/38 subjects) in the trial of Lindberg
et al [4].
Phosphorus binders and vitamin D sterols in trials
assessing the efficacy of cinacalcet
Management of phosphorus binders and vitamin D
sterols were left to the clinical discretion of the site in-
vestigators in each of these trials. While there was a
demonstrated differential decrement in both serum cal-
cium and phosphorus for the groups receiving cinacalcet
compared with placebo, the dose of phosphorus binders
and vitamin D sterols between groups did not change ap-
preciably from baseline to trial completion at 26 weeks
among any of the trials [2–4]. Among patients receiv-
ing calcium-containing phosphate binders, the elemen-
tal calcium doses remained unchanged from baseline
to study conclusion in the group receiving cinacalcet,
and were not significantly different from the doses of
calcium-containing phosphate binders in the group re-
ceiving placebo (1903 vs. 1901 mg, 1630 vs. 1924 mg, P >
0.05) [3]. Among patients receiving sevelamer hydrochlo-
ride, doses were similarly unchanged in both arms (5094
vs. 4983 mg, 3777 vs. 3930 mg, P > 0.05).
Doses of both calcitriol and paricalcitriol were un-
changed from baseline through maintenance in both
treatment groups [3]. Doses of calcitriol at baseline and
study conclusion were 4.3 versus 3.4 lg per week among
the group receiving cinacalcet compared with 4.5 versus
3.2 (not statistically different, P > 0.05) for the group
receiving placebo. Doses of paricalcitriol at baseline and
study conclusion were 22.1 versus 15.6 lg per week among
the group receiving cinacalcet compared with 21.0 versus
14.0 (not statistically different, P > 0.05) for the group
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receiving placebo. Similar results were demonstrated in
the other clinical trials [2, 4].
The effect of calcimimetics on the concurrent use of
phosphorus binders and vitamin D sterols should, how-
ever, include consideration of the duration of treatment
for patients. Each of these trials was composed of two
phases lasting a total of 26 weeks. Therefore, the lack of
a demonstrable impact on dosing of phosphorus binders
is a conclusion that is appropriate only in this shorter
time frame. Whether a longer time frame of exposure to
cinacalcet may produce a differential effect remains to be
determined.
Additionally and arguably more importantly, the trial
reports do not provide information on how changes in
the doses of phosphorus-binding agents varied based on
each individual patient’s response in terms of decline
in serum calcium, or particularly among patients with
episodes of significant hypocalcemia. While the effect
of cinacalcet on lowering phosphorus may slightly di-
minish the need for phosphorus binders, arguably, the
decrement in serum calcium may slightly increase the
need for calcium supplements. Based on the consistency
with which cinacalcet causes hypocalcemia, one could
speculate on the consequence of using cinacalcet with a
non-calcium–containing phosphate binder. While the po-
tential efficacy of a calcium-containing phosphate binder
in cinacalcet-treated patients such as calcium acetate over
the use of a non-calcium–containing phosphate binder
and a calcium supplement such as calcium carbonate has
not been fully defined, the advantages of the former com-
bination are apparent.
Combining the results of three of the trials compar-
ing cinacalcet and placebo, the group receiving cinacalcet
experienced a greater success in meeting the NKF clini-
cal practice guidelines on bone and mineral metabolism’s
goals for phosphorus, calcium-phosphorus product, and
most notably calcium levels (36 vs. 54%, 36 vs. 65%, and
25 vs. 69%, respectively) [7]. Regardless of the effect on
phosphate binders and vitamin D sterols noted here, the
combination of these effects may subsequently shift the
focus from concerns over the detrimental effects of hy-
percalcemia to the demonstrated increased mortality risk
associated with hypocalcemia [8]. Data from larger trials
or the postmarketing experience will be required to vali-
date these hypotheses.
CONCLUSION
In clinical trials, cinacalcet has been effective in sup-
pressing intact PTH levels. In these trials and among
patients receiving standard care, there were no differ-
ences between groups receiving the calcimimetic agent
or placebo on the type and dose of phosphorus-binding
agents or vitamin D sterols. Among patients in these
studies, there were no reported episodes of hypercal-
cemia and a small but significant number of episodes of
hypocalcemia. Finally, average calcium and phosphorus
levels fell for patients receiving cinacalcet, as did their
average calcium-phosphorus product. Given the decre-
ment in serum calcium and phosphorus levels, as well
as calcium-phosphorus product, it may be posited that
similar results in terms of a diminished frequency of hy-
percalcemia and an increased frequency of hypocalcemia
may be expected as the used of cinacalcet becomes more
common. This shift in focus, as well as the improved abil-
ity of patients receiving cinacalcet to achieve NKF goals
for calcium and phosphorus, may result in an increase in
the use of calcium-containing phosphate binders based
on their ability to be both a phosphorus binder as well as
a calcium supplement. Continued surveillance of trends
in concomitant medications will be useful in assessing the
impact of the calcimimetic agent cinacalcet on the use of
both phosphate binders.
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